Copyright Reports & Markets. All rights reserved.

Global Cancer mTOR Inhibitors Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Cancer mTOR Inhibitors Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Cancer mTOR Inhibitors Market Size Growth Rate by Product
      • 1.4.2 Afinitor/Votubia
      • 1.4.3 Afinitor Disperz andndash; mTOR inhibitor for Rare Pediatric Brain Tumor
      • 1.4.4 Torisel (Temsirolimus)
      • 1.4.5 Evertor andndash
    • 1.5 Market by End User
      • 1.5.1 Global Cancer mTOR Inhibitors Market Size Growth Rate by End User
      • 1.5.2 Breast Cancer
      • 1.5.3 Hematological Malignancy
      • 1.5.4 Neuroendocrine Tumors
      • 1.5.5 Hepatocellular Carcinoma
      • 1.5.6 Glioblastoma
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Cancer mTOR Inhibitors Market Size
      • 2.1.1 Global Cancer mTOR Inhibitors Revenue 2014-2025
      • 2.1.2 Global Cancer mTOR Inhibitors Sales 2014-2025
    • 2.2 Cancer mTOR Inhibitors Growth Rate by Regions
      • 2.2.1 Global Cancer mTOR Inhibitors Sales by Regions
      • 2.2.2 Global Cancer mTOR Inhibitors Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Cancer mTOR Inhibitors Sales by Manufacturers
      • 3.1.1 Cancer mTOR Inhibitors Sales by Manufacturers
      • 3.1.2 Cancer mTOR Inhibitors Sales Market Share by Manufacturers
      • 3.1.3 Global Cancer mTOR Inhibitors Market Concentration Ratio (CR5 and HHI)
    • 3.2 Cancer mTOR Inhibitors Revenue by Manufacturers
      • 3.2.1 Cancer mTOR Inhibitors Revenue by Manufacturers (2014-2019)
      • 3.2.2 Cancer mTOR Inhibitors Revenue Share by Manufacturers (2014-2019)
    • 3.3 Cancer mTOR Inhibitors Price by Manufacturers
    • 3.4 Cancer mTOR Inhibitors Manufacturing Base Distribution, Product Types
      • 3.4.1 Cancer mTOR Inhibitors Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Cancer mTOR Inhibitors Product Type
      • 3.4.3 Date of International Manufacturers Enter into Cancer mTOR Inhibitors Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Cancer mTOR Inhibitors Sales by Product
    • 4.2 Global Cancer mTOR Inhibitors Revenue by Product
    • 4.3 Cancer mTOR Inhibitors Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Cancer mTOR Inhibitors Breakdown Data by End User

    6 North America

    • 6.1 North America Cancer mTOR Inhibitors by Countries
      • 6.1.1 North America Cancer mTOR Inhibitors Sales by Countries
      • 6.1.2 North America Cancer mTOR Inhibitors Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Cancer mTOR Inhibitors by Product
    • 6.3 North America Cancer mTOR Inhibitors by End User

    7 Europe

    • 7.1 Europe Cancer mTOR Inhibitors by Countries
      • 7.1.1 Europe Cancer mTOR Inhibitors Sales by Countries
      • 7.1.2 Europe Cancer mTOR Inhibitors Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Cancer mTOR Inhibitors by Product
    • 7.3 Europe Cancer mTOR Inhibitors by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Cancer mTOR Inhibitors by Countries
      • 8.1.1 Asia Pacific Cancer mTOR Inhibitors Sales by Countries
      • 8.1.2 Asia Pacific Cancer mTOR Inhibitors Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Cancer mTOR Inhibitors by Product
    • 8.3 Asia Pacific Cancer mTOR Inhibitors by End User

    9 Central & South America

    • 9.1 Central & South America Cancer mTOR Inhibitors by Countries
      • 9.1.1 Central & South America Cancer mTOR Inhibitors Sales by Countries
      • 9.1.2 Central & South America Cancer mTOR Inhibitors Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Cancer mTOR Inhibitors by Product
    • 9.3 Central & South America Cancer mTOR Inhibitors by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Cancer mTOR Inhibitors by Countries
      • 10.1.1 Middle East and Africa Cancer mTOR Inhibitors Sales by Countries
      • 10.1.2 Middle East and Africa Cancer mTOR Inhibitors Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Cancer mTOR Inhibitors by Product
    • 10.3 Middle East and Africa Cancer mTOR Inhibitors by End User

    11 Company Profiles

    • 11.1 Abraxis BioScience
      • 11.1.1 Abraxis BioScience Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Abraxis BioScience Cancer mTOR Inhibitors Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Abraxis BioScience Cancer mTOR Inhibitors Products Offered
      • 11.1.5 Abraxis BioScience Recent Development
    • 11.2 Adimab
      • 11.2.1 Adimab Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Adimab Cancer mTOR Inhibitors Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Adimab Cancer mTOR Inhibitors Products Offered
      • 11.2.5 Adimab Recent Development
    • 11.3 Celgene Corporation
      • 11.3.1 Celgene Corporation Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Celgene Corporation Cancer mTOR Inhibitors Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Celgene Corporation Cancer mTOR Inhibitors Products Offered
      • 11.3.5 Celgene Corporation Recent Development
    • 11.4 Celator Pharmaceuticals
      • 11.4.1 Celator Pharmaceuticals Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Celator Pharmaceuticals Cancer mTOR Inhibitors Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Celator Pharmaceuticals Cancer mTOR Inhibitors Products Offered
      • 11.4.5 Celator Pharmaceuticals Recent Development
    • 11.5 Eli Lilly
      • 11.5.1 Eli Lilly Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Eli Lilly Cancer mTOR Inhibitors Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Eli Lilly Cancer mTOR Inhibitors Products Offered
      • 11.5.5 Eli Lilly Recent Development
    • 11.6 Exelixis
      • 11.6.1 Exelixis Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Exelixis Cancer mTOR Inhibitors Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Exelixis Cancer mTOR Inhibitors Products Offered
      • 11.6.5 Exelixis Recent Development
    • 11.7 GlaxoSmithKline
      • 11.7.1 GlaxoSmithKline Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 GlaxoSmithKline Cancer mTOR Inhibitors Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 GlaxoSmithKline Cancer mTOR Inhibitors Products Offered
      • 11.7.5 GlaxoSmithKline Recent Development
    • 11.8 HEC Pharm
      • 11.8.1 HEC Pharm Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 HEC Pharm Cancer mTOR Inhibitors Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 HEC Pharm Cancer mTOR Inhibitors Products Offered
      • 11.8.5 HEC Pharm Recent Development
    • 11.9 Intellikine
      • 11.9.1 Intellikine Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 Intellikine Cancer mTOR Inhibitors Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 Intellikine Cancer mTOR Inhibitors Products Offered
      • 11.9.5 Intellikine Recent Development
    • 11.10 Novartis
      • 11.10.1 Novartis Company Details
      • 11.10.2 Company Business Overview
      • 11.10.3 Novartis Cancer mTOR Inhibitors Sales, Revenue and Gross Margin (2014-2019)
      • 11.10.4 Novartis Cancer mTOR Inhibitors Products Offered
      • 11.10.5 Novartis Recent Development
    • 11.11 Oneness Biotech
    • 11.12 PIQUR Therapeutics
    • 11.13 Semafore Pharmaceuticals
    • 11.14 Takeda
    • 11.15 Wyeth

    12 Future Forecast

    • 12.1 Cancer mTOR Inhibitors Market Forecast by Regions
      • 12.1.1 Global Cancer mTOR Inhibitors Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Cancer mTOR Inhibitors Revenue Forecast by Regions 2019-2025
    • 12.2 Cancer mTOR Inhibitors Market Forecast by Product
      • 12.2.1 Global Cancer mTOR Inhibitors Sales Forecast by Product 2019-2025
      • 12.2.2 Global Cancer mTOR Inhibitors Revenue Forecast by Product 2019-2025
    • 12.3 Cancer mTOR Inhibitors Market Forecast by End User
    • 12.4 North America Cancer mTOR Inhibitors Forecast
    • 12.5 Europe Cancer mTOR Inhibitors Forecast
    • 12.6 Asia Pacific Cancer mTOR Inhibitors Forecast
    • 12.7 Central & South America Cancer mTOR Inhibitors Forecast
    • 12.8 Middle East and Africa Cancer mTOR Inhibitors Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Cancer mTOR Inhibitors Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      The global Cancer mTOR Inhibitors market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Cancer mTOR Inhibitors market based on company, product type, end user and key regions.

      This report studies the global market size of Cancer mTOR Inhibitors in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Cancer mTOR Inhibitors in these regions.
      This research report categorizes the global Cancer mTOR Inhibitors market by top players/brands, region, type and end user. This report also studies the global Cancer mTOR Inhibitors market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Abraxis BioScience
      Adimab
      Celgene Corporation
      Celator Pharmaceuticals
      Eli Lilly
      Exelixis
      GlaxoSmithKline
      HEC Pharm
      Intellikine
      Novartis
      Oneness Biotech
      PIQUR Therapeutics
      Semafore Pharmaceuticals
      Takeda
      Wyeth

      Market size by Product
      Afinitor/Votubia
      Afinitor Disperz andndash; mTOR inhibitor for Rare Pediatric Brain Tumor
      Torisel (Temsirolimus)
      Evertor andndash
      Market size by End User
      Breast Cancer
      Hematological Malignancy
      Neuroendocrine Tumors
      Hepatocellular Carcinoma
      Glioblastoma

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Cancer mTOR Inhibitors market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Cancer mTOR Inhibitors market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Cancer mTOR Inhibitors companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Cancer mTOR Inhibitors submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Cancer mTOR Inhibitors are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Cancer mTOR Inhibitors market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now